Encoded secures $275m for Dravet syndrome gene therapy
Encoded Therapeutics has raised $275m in a Series F financing round to advance development of its disease-modifying therapy (DMT) for …
Post
-
-
Podcast: key readouts from ESC and ERS
It's conference season again. In this episode, the healthcare team rounds up the latest readouts and emerging themes from two …
-
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
Bayer has landed an accelerated US approval for its non-small cell lung cancer (NSCLC) therapy, Hyrnuo (sevabertinib), expanding the drug’s …
-
HHS appoints permanent FDA CBER, CDER heads
The US Department of Health and Human Services (HHS) has selected four senior leaders to assume permanent positions in the …
-
Solstice Oncology secures $225m to drive porustobart’s development for cancer
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy. The …
-
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
TwoStep Therapeutics has raised $62.5m in an oversubscribed Series A financing round to support its lead peptide-drug conjugate, TS-104, for …
-
Why China’s rise needs to be taken with a pinch of salt
A closer look at the numbers that paint China as accelerating towards global biopharma dominance and you will find indications …
-
Pharma’s R&D, commercial approach shifts amid global policy evolution
A new report from business management consultancy, Numerof & Associates has found that pharma executives are increasingly rethinking the launch …
-
ERS 2026: GB-0895 clinical results show potential of next-gen anti-TSLP for asthma
On Sunday, September 6, at the European Respiratory Society (ERS) 2026 Annual Meeting, Generate: Biomedicinesinvestigators presented pharmacodynamics and safety results …
-
Moonwalk banks $70m to progress siRNA therapy for obesity
Moonwalk Biosciences has secured $70m in an oversubscribed, Eli Lilly-backed funding round to take its non-incretin obesity candidate to the …
-
“Unparalleled opportunity”: Sandoz embarks on ambitious biosimilar growth strategy
This year, Sandoz celebrated the 20th anniversary of its – and the world's – first marketed biosimilar. But instead of …
-
Gilead launches research facility in US for new medicine development
Gilead Sciences has opened a new 182,000ft² research centre at its Foster City headquarters in California, US, for advancing medicines …
-
FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to RiboX Therapeutics’ investigational treatment …
-
Why the CNS boom owes its success to breakthroughs in neurological pathologies
Experts say we can thank an improved understanding of the biology behind central nervous system (CNS) diseases for the resurgence …
-
Quoin in line for priority review voucher if rare paediatric drug approved
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Quoin Pharmaceuticals’ candidate in development for …
